Skip to main content
. 2022 Nov 10;32(12):1068–1085. doi: 10.1038/s41422-022-00746-3

Fig. 6. HR121 provided effective protection against SARS-CoV-2 infection in rhesus macaques.

Fig. 6

a Schematic diagram of vaccination of eight rhesus macaques with HR121 plus IFA (n = 4) and IFA only (n = 4). b bAbs to HR121. c nAbs to authentic SARS-CoV-2. d nAbs to VSV-based SARS-CoV-2 main circulating pseudo-variants. e–g Viral gRNA and sgRNA in nasal swabs (e), throat swabs (f), and lung lobes (g) of SARS-CoV-2-challenged macaques. h Histopathologic scores of lung lesions from HR121-vaccinated and adjuvant control macaques. Three representative samples from upper, middle, and lower lung lobes of each macaque were stained with H&E and evaluated. Nine regions of each sample were scored independently. Each lesion was assigned with a score of: 0, no substantial findings; 1, minimal; 2, mild; 3, severe. Scores were added for each lesion in one sample (Two-way ANOVA). i Representative photographs of pulmonary H&E staining in the HR121-vaccinated and adjuvant control macaques, in which thickened alveolar walls (green arrow), and lymphoid proliferation (blue arrow) are marked. Other lesions in lung tissues were labeled in Supplementary information, Fig. S8. j Body weight changes in SARS-CoV-2-challenged macaques. Data are presented as means ± SEM (Two-way ANOVA). k Body temperature changes in SARS-CoV-2-challenged macaques. Data are presented as means ± SEM (Two-way ANOVA). In b–g, each circle/dot represents a macaque, and dashed lines mean the limit of quantification. In b–d, data are presented as geometric mean ± geometric SD (two-tailed Wilcoxon test). In e–g, data are presented as median ± interquartile range (two-tailed Wilcoxon test).